New drug combo shows promise in early cancer trial
NCT ID NCT06422520
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells, alone or with an immunotherapy (tislelizumab). The goal is to find a safe dose and see if it shrinks tumors in people with advanced solid cancers that have not responded to other treatments. About 120 participants will receive the drug for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215-5418, United States
-
Florida Cancer Specialist Research Institute Lake Nona
Orlando, Florida, 32827-7400, United States
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Next Oncology
San Antonio, Texas, 78229-6028, United States
-
One Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
St Vincents Hospital Melbourne
Fitzroy, Victoria, VIC 3065, Australia
-
The Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Westmead Hospital
Westmead, New South Wales, NSW 2145, Australia
Conditions
Explore the condition pages connected to this study.